Improved endothelial function after endothelin receptor blockade in patients with systemic sclerosis

Area of Science:

• Vascular biology
• Rheumatology
• Pharmacology

Background:

• Systemic sclerosis (SSc) is associated with impaired endothelium-dependent vasodilator function, a potential contributor to vascular damage.
• The role of the endothelin 1 (ET-1) system in endothelial dysfunction in SSc requires further investigation.

Purpose of the Study:

• To investigate the involvement of the endothelin 1 (ET-1) system in endothelial dysfunction in patients with systemic sclerosis (SSc).
• To assess the impact of endothelin A (ETA) receptor antagonism on endothelial function in SSc.

Main Methods:

• Forearm blood flow responses to acetylcholine (ACh) and sodium nitroprusside (SNP) were measured in 12 SSc patients and healthy controls.
• Intraarterial infusions of saline and the selective ETA receptor antagonist BQ-123 were administered.
• Plethysmography was used to assess blood flow changes.

Main Results:

• Patients with SSc exhibited blunted vasodilator responses to ACh compared to controls, while SNP responses were similar.
• ETA receptor antagonism significantly potentiated ACh-induced vasodilation in SSc patients, indicating enhanced ET-1-mediated vasoconstriction.
• The beneficial effects of ETA receptor blockade were more pronounced in patients with diffuse cutaneous SSc (dcSSc) than limited cutaneous SSc (lcSSc).

Conclusions:

• Increased ET-1-dependent vasoconstrictor tone is a significant factor in SSc, especially in the dcSSc subtype.
• ETA receptor antagonism demonstrates potential vasculoprotective effects by improving endothelial function in SSc.
• Targeting the ET-1 pathway represents a promising therapeutic strategy for SSc patients.